| Literature DB >> 21928354 |
Abstract
In a non-inferiority trial to assess a new investigative treatment, there may need to be consideration of an indirect comparison with placebo using the active control in the current trial. We can, therefore, use the fact that there is a common active control in the comparisons of the investigative treatment and placebo. In analysing a non-inferiority trial, the ABC of: Assay sensitivity, Bias minimisation and Constancy assumption needs to be considered. It is highlighted how the ABC assumptions can potentially fail when there is placebo creep or a patient population shift. In this situation, the belief about the placebo response expressed in terms of a prior probability in Bayesian formulation could be used with the observed treatment effects to set the non-inferiority limit.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21928354 DOI: 10.1002/pst.517
Source DB: PubMed Journal: Pharm Stat ISSN: 1539-1604 Impact factor: 1.894